spacer
home > epc > winter 2003 > hyperbaric oxygen therapy and diabetes
PUBLICATIONS
European Pharmaceutical Contractor

Hyperbaric Oxygen Therapy and Diabetes

Treatment and Benefits of Hyperbaric Oxygen Therapy

HBO therapy is the provision of oxygen at raised pressure. Oxygen (O2) behaves like a drug with response depending on the dose:
Air at 1 atmosphere gives a dose of 0.2 bar O2
100 per cent oxygen at 1 atmosphere gives a dose of 1 bar O2
100 per cent oxygen at 2.8 bar gives a dose of 2.8 bar O2 (that is 14 times the dose of O2 compared with air at 1 atmosphere)

Patients breathe the oxygen via a mask, hood or ventilator at pressures above 1 atmosphere (bar) and are treated in a recompression chamber, where they are accompanied by a doctor, nurse or attendant. The pressure in the chamber is raised with compressed air. The attendants will therefore breathe this air for most of the treatment duration, and at designated times they will have to breathe oxygen which lowers the risk of decompression illness.

Patients will receive between two and 40 treatments depending on the medical condition being treated. Typically patients with decompression illness or carbon monoxide poisoning may only require between one and three treatment sessions, while patients with difficult wounds may require up to 40. The pressure in the chamber is raised to between 2.4 and 2.8 bar, and each treatment will last from two to eight hours, again depending on the medical condition.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Sara Hasan, Hyperbaric Nurse Consultant, Peter Dodds, Manager, Hyperbaric Medicine Unit, and Phil Catling, Business Group Manager, Electro-Optic Systems at QinetiQ

Sara Hasan trained at St Mary's Hospital in Paddington. She has over 20 years' nursing experience, mostly in critical care, and joined the Hyperbaric Medicine Unit at Haslar in 1997 where she is a Hyperbaric Nurse Consultant.

Peter Dodds is responsible for the day-to-day running of the Hyperbaric Medicine Unit. His technical experience in this area goes back to 1980 when he first became involved in experimental diving programmes.

Phil Catling has over 30 years' experience in human factors and avionics systems R&D. He manages QinetiQ's diabetic retinopathy programme and is also active in progressing other health-related activities.

spacer
Sara Hasan
spacer
spacer
spacer
Peter Dodds
spacer
spacer
spacer
Phil Catling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius Stedim Biotech Launches New Services for Mammalian Cell Bank Manufacturing

GOETTINGEN, Germany and GLASGOW, UK, August 08, 2019 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading partner of the biopharmaceutical industry, today announced the launch of new services for mammalian cell bank manufacture under GMP conditions. These services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced contract testing organization (CTO) based in Glasgow, UK, and in Cambridge, Massachusetts, USA.
More info >>

White Papers

e-tools enhance clinical trial performance

e-novex

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement